Jared JD - Intercept Pharmaceuticals G Counsel
Insider
Jared JD is G Counsel of Intercept Pharmaceuticals
| Age | 55 |
| Phone | 646 747 1000 |
| Web | https://www.interceptpharma.com |
Intercept Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.0723) % which means that it has lost $0.0723 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6402) %, meaning that it created substantial loss on money invested by shareholders. Intercept Pharmaceuticals' management efficiency ratios could be used to measure how well Intercept Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Intercept Pharmaceuticals currently holds 332.67 M in liabilities with Debt to Equity (D/E) ratio of 411.2, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Intercept Pharmaceuticals has a current ratio of 3.16, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Intercept Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| William Ciambrone | Sarepta Therapeutics | 60 | |
| BSc BSc | Hepion Pharmaceuticals | 66 | |
| Paul MD | Madrigal Pharmaceuticals | 81 | |
| Peter Facchini | Enveric Biosciences | 61 | |
| Michael Esq | TG Therapeutics | 59 | |
| Valerie MD | Elevation Oncology | 46 | |
| FACS FACS | PTC Therapeutics | 50 | |
| CPA CPA | TG Therapeutics | 42 | |
| Timothy Rolph | Akero Therapeutics | 71 | |
| Remy Sukhija | Madrigal Pharmaceuticals | 52 | |
| Robert Waltermire | Madrigal Pharmaceuticals | 61 | |
| Weidong Zhong | Terns Pharmaceuticals | 58 | |
| Launa Aspeslet | Hepion Pharmaceuticals | N/A | |
| Eric Pauwels | PTC Therapeutics | 63 | |
| Daren Ure | Hepion Pharmaceuticals | N/A | |
| David Glynn | Krystal Biotech | N/A | |
| Avani Kanubaddi | Enveric Biosciences | 51 | |
| MS MBA | Krystal Biotech | 60 | |
| Todd MD | Hepion Pharmaceuticals | 55 | |
| Marianne Mancini | Viking Therapeutics | 60 | |
| William JD | Akero Therapeutics | 51 | |
Management Performance
| Return On Equity | -0.64 | |||
| Return On Asset | -0.0723 |
Intercept Pharmaceuticals Leadership Team
Elected by the shareholders, the Intercept Pharmaceuticals' board of directors comprises two types of representatives: Intercept Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Intercept. The board's role is to monitor Intercept Pharmaceuticals' management team and ensure that shareholders' interests are well served. Intercept Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Intercept Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Linda Richardson, Ex Officer | ||
| Andrew Saik, Chief Officer | ||
| David Ford, Chief Human Resource Officer | ||
| Jerome Durso, CEO Pres | ||
| Mark MD, Advisor Founder | ||
| Jared JD, G Counsel | ||
| Rocco Venezia, Chief Treasurer | ||
| Paul Nitschmann, VP Affairs | ||
| Nareg Sagherian, Ex Relations | ||
| MD MPH, Pres Officer |
Intercept Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Intercept Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.64 | |||
| Return On Asset | -0.0723 | |||
| Profit Margin | (0.19) % | |||
| Operating Margin | 0.02 % | |||
| Current Valuation | 695.84 M | |||
| Shares Outstanding | 41.81 M | |||
| Shares Owned By Insiders | 3.12 % | |||
| Shares Owned By Institutions | 81.30 % | |||
| Number Of Shares Shorted | 10.19 M | |||
| Price To Earning | (3.88) X |
Thematic Opportunities
Explore Investment Opportunities
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Other Consideration for investing in Intercept Stock
If you are still planning to invest in Intercept Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Intercept Pharmaceuticals' history and understand the potential risks before investing.
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |